- Trials with a EudraCT protocol (232)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
232 result(s) found for: Gastric (Stomach) Cancer.
Displaying page 6 of 12.
| EudraCT Number: 2020-004163-12 | Sponsor Protocol Number: 2020-012-GLOB1 | Start Date*: 2021-11-04 | |||||||||||||||||||||||||||||||
| Sponsor Name:Hutchison MediPharma Limited | |||||||||||||||||||||||||||||||||
| Full Title: An Open-Label Phase Ib/II Study of Surufatinib in Combination with Tislelizumab in Subjects With Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced Solid Tumors | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: ES (Ongoing) FR (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
| EudraCT Number: 2007-000348-28 | Sponsor Protocol Number: BO15943 | Start Date*: 2007-08-30 |
| Sponsor Name:F. Hoffmann-La Roche Ltd | ||
| Full Title: A single arm, multi-centre, international, continuation trial of recombinant humanized antibody Herceptin® (trastuzumab) in patients with HER2 overexpressing tumors. | ||
| Medical condition: To continue to provide treatment to those patients that may still be on treatment at the moment of the final data base closure/clinical cut-off of a clinical trials in which Herceptin® is investiga... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) PT (Completed) FR (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-018092-14 | Sponsor Protocol Number: CRAD001RDE35T | Start Date*: Information not available in EudraCT | ||||||||||||||||
| Sponsor Name:Krankenhaus Nordwest GmbH | ||||||||||||||||||
| Full Title: A randomized, double-blind, multi-center phase III study evaluating paclitaxel with and without RAD001 in patients with gastric carcinoma who have progressed after therapy with a fluoropyrimidine/p... | ||||||||||||||||||
| Medical condition: advanced (i.e. inoperable, recurrent or metastatic) gastric cancer or adenocarcinoma of the esophagogastric junction | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2011-002570-23 | Sponsor Protocol Number: CAUY922A2205 | Start Date*: 2011-12-22 | ||||||||||||||||
| Sponsor Name:Novartis Pharma Services AG | ||||||||||||||||||
| Full Title: An open-label, single-arm, multi-center phase II study to evaluate the efficacy and safety of AUY922 in combination with trastuzumab standard therapy as second-line treatment in patients with HER2-... | ||||||||||||||||||
| Medical condition: Patients with documented advanced HER2 positive gastric cancer progressing after clinical benefit to 1st line treatment with trastuzumab containing treatment. Clinical benefit is defined as overall... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: BE (Prematurely Ended) DE (Completed) ES (Prematurely Ended) IT (Prematurely Ended) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2022-002840-29 | Sponsor Protocol Number: D7986C00001 | Start Date*: 2023-01-23 | ||||||||||||||||
| Sponsor Name:AstraZeneca AB | ||||||||||||||||||
| Full Title: A Master Protocol of an Open-Label, Multi-Drug, Multi-Centre, Phase II Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Novel Combinations in Participan... | ||||||||||||||||||
| Medical condition: Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Ongoing) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2020-001075-32 | Sponsor Protocol Number: RE-ExPEL | Start Date*: 2020-08-03 | ||||||||||||||||
| Sponsor Name:Institut für Klinische Krebsforschung IKF GmbH | ||||||||||||||||||
| Full Title: RE-ExPEL A pilot study of ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure... | ||||||||||||||||||
| Medical condition: advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2008-001605-42 | Sponsor Protocol Number: 20060317 | Start Date*: 2008-07-14 | |||||||||||
| Sponsor Name:Amgen Inc | |||||||||||||
| Full Title: A Multicenter, Double-Blind, 3-Arm, Phase 1b/2 Study in Subjects with Unresectable Locally Advanced or Metastatic Gastric or Esophagogastric Junction Adenocarcinoma to Evaluate the Safety and Effi... | |||||||||||||
| Medical condition: Unrespectable locally advanced or metastatic gastric or esophagogastric unction adenocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) ES (Completed) IT (Prematurely Ended) GR (Completed) BE (Completed) HU (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2008-006128-79 | Sponsor Protocol Number: GASTRIC-3 | Start Date*: 2009-04-14 | |||||||||||
| Sponsor Name:Arbeitsgemeinschaft medikamentöse Tumortherapie gemeinnützige GmbH | |||||||||||||
| Full Title: Phase II Study of Oxaliplatin / Irinotecan / Bevacizumab Followed by Docetaxel / Bevacizumab in Inoperable Locally Advanced or Metastatic Gastric Cancer Patients | |||||||||||||
| Medical condition: Unresectable locally advanced or metastatic Gastric Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: AT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-000230-29 | Sponsor Protocol Number: CA209-358 | Start Date*: 2015-09-29 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Bristol-Myers Squibb International Corporation | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab and Nivolumab plus Ipilimumab in Subjects with Virus-Positive and Virus-Negative Solid Tumors | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Virus-associated tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: NL (Completed) DE (Completed) BE (Completed) GB (GB - no longer in EU/EEA) ES (Completed) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2011-001507-13 | Sponsor Protocol Number: AIO-STO-0310 | Start Date*: 2011-10-24 | ||||||||||||||||
| Sponsor Name:AIO-Studien-gGmbH | ||||||||||||||||||
| Full Title: Multicenter, explorative phase II study of perioperative 5-FU, leucovorin, docetaxel, and oxaliplatin (FLOT) in combination with Trastuzumab in patients with HER2-positive, locally advanced resecta... | ||||||||||||||||||
| Medical condition: HER2-positive, locally advanced, resectable adenocarcinoma of the gastroesophageal junction or stomch | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-016019-39 | Sponsor Protocol Number: TPU-S1303 | Start Date*: 2011-02-14 | |||||||||||
| Sponsor Name:Taiho Oncology, Inc. | |||||||||||||
| Full Title: AN OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 STUDY OF S-1 AND CISPLATIN COMPARED WITH 5-FU AND CISPLATIN IN PATIENTS WITH METASTATIC DIFFUSE GASTRIC CANCER PREVIOUSLY UNTREATED WITH CHEMOTHERAPY | |||||||||||||
| Medical condition: Metastatic Diffuse Gastric Cancer | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) BE (Completed) HU (Completed) GB (Completed) ES (Completed) PT (Completed) EE (Completed) IT (Prematurely Ended) BG (Completed) LT (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2015-004627-31 | Sponsor Protocol Number: M15CRI | Start Date*: 2017-06-20 | |||||||||||||||||||||
| Sponsor Name:The Netherlands Cancer Institute | |||||||||||||||||||||||
| Full Title: A multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery vs. neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery vs. neo-adjuvant chemorad... | |||||||||||||||||||||||
| Medical condition: TNM 7th ed stage IB-IIIC gastric adenocarcinoma (histologically proven); tumour bulk has to be in the stomach but may involve gastro-oesophageal junction | |||||||||||||||||||||||
|
|||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||
| Trial protocol: NL (Trial now transitioned) | |||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||
| EudraCT Number: 2006-000811-12 | Sponsor Protocol Number: ST03 | Start Date*: 2008-01-31 | ||||||||||||||||
| Sponsor Name:Medical Research Council Clinical Trials Unit | ||||||||||||||||||
| Full Title: A Randomised Phase II/III trial of peri-operative Chemotherapy with or without Bevacizumab in Operable Oesophagogastric Adenocarcinoma and A Feasibility Study Evaluating Lapatinib in HER-2 Positive... | ||||||||||||||||||
| Medical condition: Patients with histologically verfied lower oesophageal, Siewert Type I, II or III oesophagogastric junction or gastric adenocarcinoma. Type III or gastric tumours should be stage 1b (T1N1, T2a/bN0... | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2009-010730-21 | Sponsor Protocol Number: TEL0805 | Start Date*: 2009-06-17 | |||||||||||
| Sponsor Name:ACT BIOTECH, Inc | |||||||||||||
| Full Title: A Phase 2 Open-Label Study Evaluating the Efficacy and Safety of Telatinib in Combination with Chemotherapy as First-line Therapy in Subjects with Advanced Gastric Cancer Estudio de fase 2, abiert... | |||||||||||||
| Medical condition: Patient population includes patients with Advance gastric cancer, with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1. Patients must have measurable disease and must not have ... | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2010-022793-14 | Sponsor Protocol Number: AB10007 | Start Date*: 2011-08-05 | ||||||||||||||||
| Sponsor Name:AB Science | ||||||||||||||||||
| Full Title: A prospective, multicentre, open-label, randomised, uncontrolled, phase 1/2 study to evaluate the efficacy and safety of masitinib in combination with 5-fluorouracil (5-FU) or capecitabine, or masi... | ||||||||||||||||||
| Medical condition: gastric or gastro-oesophageal junction metastatic adenocarcinoma | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
| Trial protocol: FR (Completed) | ||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||
| EudraCT Number: 2019-004323-20 | Sponsor Protocol Number: BNT211-01 | Start Date*: 2020-06-30 | |||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:BioNTech Cell & Gene Therapies GmbH | |||||||||||||||||||||||||||||||||||||||||||
| Full Title: Phase 1/2a, first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate safety and preliminary efficacy of CLDN6 CAR-T with or without CLDN6 RNA-LPX in patients with CLDN6-... | |||||||||||||||||||||||||||||||||||||||||||
| Medical condition: CLDN6-positive relapsed or refractory advanced solid tumors | |||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: DE (Trial now transitioned) NL (Trial now transitioned) SE (Trial now transitioned) | |||||||||||||||||||||||||||||||||||||||||||
| Trial results: (No results available) | |||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2018-003172-12 | Sponsor Protocol Number: KY1044-CT01 | Start Date*: 2019-03-07 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Sponsor Name:Kymab Ltd | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Full Title: A Phase 1/2, open-label, multi-center study of the safety and efficacy of KY1044 as single agent and in combination with anti-PD-L1 (atezolizumab) in adult patients with selected advanced malignancies | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Medical condition: Advanced/metastatic malignancies, and preferred indications: head and neck squamous cell carcinoma (HNSCC), non-small cell lung cancer (NSCLC), hepatocellular carcinoma (HCC), esophageal cancer, ga... | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) HU (Completed) PL (Completed) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EudraCT Number: 2022-003079-41 | Sponsor Protocol Number: BOLD-100-001 | Start Date*: 2023-01-06 | ||||||||||||||||||||||||||
| Sponsor Name:Bold Therapeutics, Inc. (Bold) | ||||||||||||||||||||||||||||
| Full Title: A Phase 1b/2a Dose Escalation Study of BOLD-100 in Combination with FOLFOX Chemotherapy in Patients with Advanced Solid Tumours | ||||||||||||||||||||||||||||
| Medical condition: Colorectal Cancer Pancreatic Cancer Gastric Cancers Cholangiocarcinoma | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: IE (Trial now transitioned) | ||||||||||||||||||||||||||||
| Trial results: (No results available) | ||||||||||||||||||||||||||||
| EudraCT Number: 2005-000146-36 | Sponsor Protocol Number: EMD72000-032 | Start Date*: 2005-07-28 | |||||||||||
| Sponsor Name:Merck KGaA | |||||||||||||
| Full Title: Randomized Phase II open-label controlled study of EMD 72000 (matuzumab) in combination with the chemotherapy regimen ECX or the chemotherapy regimen ECX alone as first-line treatment in subjects w... | |||||||||||||
| Medical condition: Metastatic Esophago-gastric adenocarcinoma | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: DE (Completed) GB (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2021-002181-41 | Sponsor Protocol Number: ACT16902 | Start Date*: 2021-12-08 | |||||||||||||||||||||||||||||||
| Sponsor Name:Sanofi-Aventis Recherche & Developpement | |||||||||||||||||||||||||||||||||
| Full Title: A Phase 2 non-randomized, open-label, multi-cohort, multi-center study assessing the clinical benefit of SAR444245 (THOR-707) combined with other anticancer therapies for the treatment of participa... | |||||||||||||||||||||||||||||||||
| Medical condition: Advanced and metastatic gastrointestinal cancer | |||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||||||||||||||||||||||
| Trial protocol: FR (Completed) DE (Completed) IT (Prematurely Ended) BE (Completed) ES (Prematurely Ended) NL (Completed) | |||||||||||||||||||||||||||||||||
| Trial results: View results | |||||||||||||||||||||||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.
